955112-52-4

Basic information

• Product Name: 2-chloro-4-(tert-butoxycarbonyl-methylamino)pyrimidine
• Synonyms: 2-chloro-4-(tert-butoxycarbonyl-methylamino)pyrimidine
• CAS NO: 955112-52-4
• Molecular Formula: C10H14ClN3O2
• Molecular Weight: 243.69006
• Mol File: 955112-52-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-chloro-4-(tert-butoxycarbonyl-methylamino)pyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-4-(tert-butoxycarbonyl-methylamino)pyrimidine(955112-52-4)
• EPA Substance Registry System: 2-chloro-4-(tert-butoxycarbonyl-methylamino)pyrimidine(955112-52-4)

Safety Data

• Hazardous Substances Data: 955112-52-4(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 75833-38-4 2-chloro-pyrimidine-4-carbonitrile 
• 66131-68-8 2-chloro-N-methylpyrimidine-4-amine 

Relevant articles and documents

SUBSTITUTED 1,2,3-TRIAZOLES AS NR2B-SELECTIVE NMDA MODULATORS

Substituted 1,2,3-triazoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

High-efficacy 5-HT1A agonists for antidepressant treatment: A renewed opportunity

We report the discovery of novel 5-HT1A receptor agonists and describe the process that led to the antidepressant candidate 9 (F 15599). 9 has nanomolar affinity for 5-HT1A binding sites and is over 1000-fold selective with respect to the other 5-HT1 receptor subtypes, 5-HT2-7 receptor families, and also numerous GPCRs, transporters, ion channels, and enzymes. In a cellular model of signal transduction, 9 activates h5-HT1A receptors with an efficacy superior to that of the prototypical 5-HT1A agonist (±)-8-OH-DPAT and comparators undergoing clinical trials. After acute oral administration in rats, 9 totally reverses immobility in the forced swimming test and produces behaviors characteristic of 5-HT1A receptor activation. However, these effects occurred at widely separated doses, suggesting that 9 discriminates between distinct populations of 5-HT1A receptors. While the clinical relevance of these observations is still unknown, this opens new perspectives for the treatment of depressive disorders.